CA-ALPHAWAVE-SEMI
25.3.2024 14:01:35 CET | Business Wire | Press release
Alphawave Semi (LSE: AWE), a global leader in high-speed connectivity and compute solutions for the world’s technology infrastructure, today announced its collaboration with InnoLight Technology, the leader in data center optics, to bring a low power, low latency linear pluggable optics (LPO) demonstration to OFC 2024. Operating at 64 Gbps per lane, this demonstration showcases Alphawave Semi’s PCIe 6.0® subsystem (Controller + PHY) with InnoLight’s LPO OSFP optics, breaking down barriers to disaggregated networking and enabling connectivity at the datacenter scale. By delivering a complete PCIe 6.0 subsystem featuring Alphawave Semi’s controller IP matched with its industry-leading proven PAM4 SerDes PHY and by collaborating with InnoLight as an industry-leading optics supplier, Alphawave Semi is fostering an ecosystem for accelerating the deployment of optical connectivity and memory coherency solutions, which are essential for scaling AI workloads in next-generation data center infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325631180/en/
Low Latency Linear Pluggable Optics with PCIe 6.0® Subsystem for High-Performance AI Infrastructure (Graphic: Business Wire)
Osa Mok, Chief Marketing Officer at InnoLight, said, “We are pleased with the collaboration between Alphawave Semi and InnoLight, which demonstrates PCIe 6.0 optical connectivity that offers both low power consumption and low latency, tailored to meet the demanding requirements of high-bandwidth and high-density AI networks. Alphawave Semi’s PAM4 DSP physical layer technology, leveraged with InnoLight’s LPO OSFP, empowers hyperscalers to implement next-generation disaggregated, composable networks.“
Tony Chan Carusone, CTO at Alphawave Semi, said, “We see our collaboration with InnoLight as a significant driver for accelerating the adoption of PCIe technology over optics. The combination of InnoLight’s market-leading optical solution with Alphawave Semi’s robust DSP technology showcases how PCIe technology over optics can enable our customers to massively scale connectivity for their compute and data processing AI workloads.”
Live Demonstration at OFC Exhibit Hall, InnoLight Booth 2625
Attendees can experience a live demonstration of low power, low latency linear pluggable optics (LPO). Operating at 64 Gbps per lane, it showcases Alphawave Semi’s PCIe 6.0 subsystem (Controller + PHY) with InnoLight’s LPO OSFP optics.
More on Alphawave Semi’s PCIe Portfolio: Alphawave Semi’s PCI-Express and CXL Solution
The Alphawave Semi PCIe Controller + PHY subsystem is an extremely power-efficient, low-latency, and highly reliable interface IP, having been built off the industry’s most successful PAM4 SerDes IP. It is available on the most advanced technology nodes. In AI and high-performance computing (HPC) systems where memory performance is key, the Alphawave Semi PCIe 6.0 Subsystem can be expanded to support CXL 3.0 with a PCIe and CXL Controller and enable memory coherency at the data center level.
InnoLight offers a wide range of low power, low latency 400G, 800G, and 1.6T LPO solutions for AI workloads at data center scale, with a silicon photonics platform, with expected capabilities to support PCIe Gen 6 and beyond optical connectivity. InnoLight is also a founding member of LPO-MSA (www.lpo-msa.org), and is actively working with the industry ecosystem to promote wide adoption of LPO solutions for AI networking and computing applications.
PCI-SIG®, PCI Express®, and PCIe ® are registered trademarks and/or service marks of PCI-SIG
About Alphawave Semi
Alphawave Semi is a global leader in high-speed connectivity and compute silicon for the world's technology infrastructure. Faced with the exponential growth of data, Alphawave Semi's technology services a critical need: enabling data to travel faster, more reliably, and with higher performance at lower power. We are a vertically integrated semiconductor company, and our IP, custom silicon, and connectivity products are deployed by global tier-one customers in data centers, compute, networking, AI, 5G, autonomous vehicles, and storage. Founded in 2017 by an expert technical team with a proven track record in licensing semiconductor IP, our mission is to accelerate the critical data infrastructure at the heart of our digital world. To find out more about Alphawave Semi, visit: awavesemi.com.
Alphawave Semi and the Alphawave Semi logo are trademarks of Alphawave IP Group plc. All rights reserved.
About InnoLight Technology
InnoLight is a world leader in providing a wide range of high-speed optical solutions for optical communication networking, especially for AI and Data Center applications, with global footprints in California, Singapore, Thailand, Taiwan, and Suzhou China. For more information, please visit www.innolight.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325631180/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns7.7.2026 07:00:00 CEST | Press release
World’s most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, with the most important attributes of good skin quality identified as smooth, hydrated and glowing skin1 Results show that skin quality has an impact on quality of life for 85% of people, with more than a third feeling self-conscious, insecure or anxious due to poor skin quality1 In response to clinicians’ calls for a universal assessment tool to help address these concerns, Galderma supported leading experts in the development of the Skin Quality Assessment Scale; a holistic, science-based tool to evaluate skin quality comprehensively and guide personalized, long-term treatment planning2 At Galderma, we champion skin quality by providing insights, tools, and solutions to better understand and address a wide spectrum of concerns, helping people take pride and feel comfortable in their own skin at e
Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 04:00:00 CEST | Press release
Clinical evidence–backed postbiotic supports mood and well-being with formulation flexibility for diverse applications Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing aw
Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 02:00:00 CEST | Press release
Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom